US 8652787
Use of ERBB4 as a prognostic and therapeutic marker for melanoma
granted A61PA61P35/00
Quick answer
US patent 8652787 (Use of ERBB4 as a prognostic and therapeutic marker for melanoma) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Feb 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61P, A61P35/00